Genomics, the study of genes and their functions, is no longer just a niche scientific pursuit; it’s reshaping how we understand human health and disease. Over the last two decades, gene sequencing costs have dropped significantly, making it more affordable, accurate, and faster to map a person’s entire genome. This shift is accelerating discoveries and laying the foundation for a new era of personalized medicine, where treatments are tailored to an individual’s genetic profile.
As this field continues to evolve, companies like Illumina, Inc. (ILMN), BioNTech SE (BNTX), and Bio-Techne Corporation (TECH) are leading the charge, unlocking the secrets of DNA to revolutionize healthcare.
